Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKFree Report) in a research report report published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 1.8 %

Shares of Evoke Pharma stock opened at $0.65 on Friday. The company has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $1.06. Evoke Pharma has a 12-month low of $0.56 and a 12-month high of $3.70. The company has a current ratio of 3.50, a quick ratio of 3.27 and a debt-to-equity ratio of 9.29. The stock has a market cap of $2.17 million, a price-to-earnings ratio of -0.29 and a beta of 0.21.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Featured Articles

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.